The Management of Patients after Surgical Treatment of Maxillofacial Tumors

Table 1

Baseline characteristics.

	% ()
Age	12–93 years	58.36 ± 7.56
Gender
Female	44.33 (219/494)
Male	55.67 (275/494)
Postoperative loss
Group I	44.75 (226/495)
Bone loss^1	92.03 (208/226)
Class I	41.83 (87/208)
Class II	27.41 (57/208)
Class III	6.73 (14/208)
Class IV	8.17 (17/208)
Class V	2.88 (6/208)
Class VI	12.98 (27/208)
Group II	47.37 (234/494)
Bone loss^2	69.23 (162/234)
Class A	40.12 (65/162)
A1	40.00 (26/65)
A2	46.15 (30/65)
A3	13.85 (9/65)
Class B	27.16 (44/162)
B1	9.09 (4/44)
B2	75.00 (33/44)
B3	15.91 (7/44)
Class C	32.72 (53/162)
C1	94.34 (50/53)
C2	5.66 (3/53)
C3	0.00 (0/53)
Group III	3.44 (17/494)
Group IV	3.44 (17/494)
Supplementary treatment	69.63 (344/494)
Radiotherapy	85.47 (294/344)
Chemotherapy	4.65 (16/344)
Radio- and chemotherapy	9.88 (34/344)
Cause of surgical treatment
Squamous carcinoma	66.40 (328/494)
Ameloblastoma	3.24 (16/494)
Tumor mixtus	2.43 (12/494)
Adenocarcinoma	2.02 (10/494)
Other	25.91 (128/494)

Aramany’s classification; ²Furuta classification.